全文获取类型
收费全文 | 669篇 |
免费 | 27篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 50篇 |
妇产科学 | 13篇 |
基础医学 | 62篇 |
口腔科学 | 32篇 |
临床医学 | 50篇 |
内科学 | 203篇 |
皮肤病学 | 16篇 |
神经病学 | 14篇 |
特种医学 | 154篇 |
外科学 | 25篇 |
综合类 | 12篇 |
预防医学 | 24篇 |
眼科学 | 3篇 |
药学 | 24篇 |
中国医学 | 1篇 |
肿瘤学 | 17篇 |
出版年
2024年 | 1篇 |
2022年 | 1篇 |
2021年 | 11篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 11篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 11篇 |
2014年 | 23篇 |
2013年 | 19篇 |
2012年 | 10篇 |
2011年 | 22篇 |
2010年 | 33篇 |
2009年 | 35篇 |
2008年 | 35篇 |
2007年 | 22篇 |
2006年 | 15篇 |
2005年 | 15篇 |
2004年 | 13篇 |
2003年 | 15篇 |
2002年 | 4篇 |
2001年 | 9篇 |
2000年 | 10篇 |
1999年 | 13篇 |
1998年 | 28篇 |
1997年 | 38篇 |
1996年 | 48篇 |
1995年 | 31篇 |
1994年 | 25篇 |
1993年 | 36篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1990年 | 12篇 |
1989年 | 10篇 |
1988年 | 12篇 |
1987年 | 18篇 |
1986年 | 21篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 18篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 1篇 |
1977年 | 9篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1971年 | 1篇 |
排序方式: 共有702条查询结果,搜索用时 31 毫秒
71.
72.
Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers 总被引:6,自引:0,他引:6
Linthorst GE Vedder AC Aerts JM Hollak CE 《Clinica chimica acta; international journal of clinical chemistry》2005,353(1-2):201-203
INTRODUCTION: Recently, a method to analyse dried whole blood spots to diagnose Fabry disease (deficiency of the lysosomal enzyme alpha-Gal A) was described. However given its X-linked inheritance female Fabry patients can exhibit normal alpha-Gal A activities. This could lead to underestimation in screening females for Fabry disease using this method. METHODS: alpha-Gal A activity was measured in dried whole blood spots of 21 females with documented Fabry disease. RESULTS: Only 13/21 (67%) had reduced alpha-Gal A activities, concluding that one-third of female carriers would not be identified during screening. Additional determination of alphaGlucosidase activity (alphaGlu) and the construction of an alphaGal/alphaGlu ratio did not increase sensitivity of the assay. CONCLUSION: Assays using alpha-Gal activity for determination of Fabry disease in females have a high false-negative value. Screening for alpha-Gal A deficiency by means of whole blood spots should not be performed in a females. 相似文献
73.
In contrast to the murine system, long-term hamster bone marrow suspension cultures maintain proliferation of both pluripotent and committed stem cells in the absence of an adherent layer and without addition of exogenous factors, such as hydrocortisone. Addition of pokeweed-mitogen-stimulated hamster spleen conditioned medium (SCM) to these long-term suspension cultures produces an increase in the number of mixed colonies assayed in soft-agar, These mixed colonies, which contained four cell lineages--granulocytic, erythroid, megakaryocytic, and macrophage--could be generated from cells grown in suspension for over 6 mo. Addition of SCM also induces an initial rapid expansion of the myeloid compartment, and this expansion results in 70% of the cells being terminally differentiated granulocytes. In contrast, addition of SCM to hamster bone marrow cultures containing both adherent cells and hematopoietic stem cells produced no change in the number of mixed colonies generated in the culture. This system allows the in vitro study of the process of stem cell proliferation and differentiation and also provides a means to examine the relationship of adherent and supernatant bone marrow populations. 相似文献
74.
75.
Epstein–Barr virus (EBV) is a ubiquitous gamma‐herpesvirus that establishes a lifelong persistent infection in the oral cavity and is intermittently shed in the saliva. EBV exhibits a biphasic life cycle, supported by its dual tropism for B lymphocytes and epithelial cells, which allows the virus to be transmitted within oral lymphoid tissues. While infection is often benign, EBV is associated with a number of lymphomas and carcinomas that arise in the oral cavity and at other anatomical sites. Incomplete association of EBV in cancer has questioned if EBV is merely a passenger or a driver of the tumorigenic process. However, the ability of EBV to immortalize B cells and its prevalence in a subset of cancers has implicated EBV as a carcinogenic cofactor in cellular contexts where the viral life cycle is altered. In many cases, EBV likely acts as an agent of tumor progression rather than tumor initiation, conferring malignant phenotypes observed in EBV‐positive cancers. Given that the oral cavity serves as the main site of EBV residence and transmission, here we review the prevalence of EBV in oral malignancies and the mechanisms by which EBV acts as an agent of tumor progression. 相似文献
76.
77.
In a previous study we have shown that monoclonal antibody F1 (MoAb F1), directed against an epitope on the heavy chain of factor XII distinct from the binding site for anionic surfaces, is able to activate factor XII in plasma (Nuijens JH, et al: J Biol Chem 264; 12941, 1989). Here, we studied in detail the mechanism underlying the activation of factor XII by MoAb F1 using purified proteins. Formation of factor XIIa was assessed by measuring its amidolytic activity towards the chromogenic substrate H-D-Pro-Phe-Arg-pNA (S-2302) in the presence of soybean trypsin inhibitor and by assessing cleavage on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Upon incubation with MoAb F1 alone, factor XII was auto-activated in a time-dependent fashion, activation being maximal after 30 hours. Factor XII incubated in the absence of MoAb F1 was hardly activated by kallikrein, whereas in the presence of MoAb F1, but not in that of a control MoAb, the rate of factor XII activation by kallikrein was promoted at least 60-fold. Maximal activation of factor XII with kallikrein in the presence of MoAb F1 was reached within 1 hour. This effect of kallikrein on the cleavage of factor XII bound to MoAb F1 was specific because the fibrinolytic enzymes plasmin, urokinase, and tissue-type plasminogen activator could not substitute for kallikrein. Also, trypsin could easily activate factor XII, but in contrast to kallikrein, this activation was independent of MoAb F1. SDS-PAGE analysis showed that the appearance of amidolytic activity correlated well with cleavage of factor XII. MoAb F1-induced activation of factor XII in this purified system was not dependent on the presence of high- molecular-weight kininogen (HK), in contrast to the activation of the contact system in plasma by MoAb F1. Experiments with deletion mutants revealed that the epitopic region for MoAb F1 on factor XII is located on the kringle domain. Thus, this study shows that binding of ligands to the kringle domain, which does not contribute to the proposed binding site for negatively charged surfaces, may induce activation of factor XII. Therefore, these findings point to the existence of multiple mechanisms of activation of factor XII. 相似文献
78.
79.
Jansen PM; Pixley RA; Brouwer M; de Jong IW; Chang AC; Hack CE; Taylor FB Jr; Colman RW 《Blood》1996,87(6):2337-2344
In previous studies, we have shown that administration of monoclonal antibody (MoAb) C6B7 against human factor XII to baboons challenged with a lethal dose of Escherichia coli abrogates activation of the contact system and modulates secondary hypotension. To evaluate the contribution of activated contact proteases to the appearance of other inflammatory mediators in this experimental model of sepsis, we studied the effect of administration of MoAb C6B7 on activation of complement and fibrinolytic cascades, stimulation of neutrophil degranulation, and release of the proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Activation of the complement system, as reflected by circulating C3b/c and C4b/c levels, was significantly reduced in five animals that had received MoAb C6B7 before a lethal dose of E coli as compared with five control animals that had been given a lethal challenge only. Inhibition of contact activation also modulated the fibrinolytic response, since the release of tissue-type plasminogen activator (t-PA) and the appearance of plasmin-alpha2-antiplasmin (PAP) complexes into the circulation was significantly attenuated upon pretreatment with anti-factor XII MoAb. In contrast, plasma levels of plasminogen activator inhibitor (PAI) were modestly enhanced in the treatment group. Degranulation of neutrophils, as assessed by circulating elastase-alpha1-protease inhibitor complexes, and release of IL-6 but not of TNF-alpha was decreased in anti-factor XII-treated animals. Observed differences in the inflammatory response between treatment and control groups were not likely due to different challenges, since the number of E coli that had been infused, as well as circulating levels of endotoxin after the challenge, were similar for both groups. These data suggest that activation of the contact system modulates directly or indirectly various mediator systems involved in the inflammatory response during severe sepsis in nonhuman primates. 相似文献
80.
Cox TM Aerts JM Andria G Beck M Belmatoug N Bembi B Chertkoff R Vom Dahl S Elstein D Erikson A Giralt M Heitner R Hollak C Hrebicek M Lewis S Mehta A Pastores GM Rolfs A Miranda MC Zimran A;Advisory Council to the European Working Group on Gaucher Disease 《Journal of inherited metabolic disease》2003,26(6):513-526
N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orallyactive iminosugar which inhibits the biosynthesis of macromolecular
substrates that accumulate pathologically in glycosphingolipidoses. Clinical trials of NB-DNJ in patients with Gaucher's disease
demonstrate the therapeutic potential of such substrate inhibitors in the glycolipid storage disorders. However, macrophage-targetted
enzyme replacement using intravenous mannose-terminated human glucocerebrosidase (imiglucerase, Cerezyme) is highly effective
in ameliorating many of the manifestations of Gaucher's disease and is a treatment in widespread use. Given that imiglucerase
and miglustat are now both licensed for the treatment of Gaucher's disease, there is a need to review their therapeutic status.
Here the treatment of type 1 (non-neuronopathic) Gaucher disease is evaluated with particular reference to the emerging role
of oral N-butyldeoxynojirimycin (miglustat) as a substrate-reducing agent. This position statement represents the consensus viewpoint
of an independent international advisory council to the European Working Group on Gaucher Disease.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献